Sharon Cantor

7PUBLICATIONS
7CO-AUTHORS
Molecular targetsProteomics and intermolecular interactions (excl. medical proteomics)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jan 21, 2025
Targeting BRCA1-deficient PARP inhibitor-resistant cells with nickases reveals nick resection as a cancer vulnerability.

Jenna M Whalen, Jillian Earley, Christi Silva

|Mar 24, 2024
FANCJ promotes PARP1 activity during DNA replication that is essential in BRCA1 deficient cells.

Ke Cong, Nathan MacGilvary, Silviana Lee

|Jan 08, 2021
Targeting translesion synthesis (TLS) to expose replication gaps, a unique cancer vulnerability.

Sumeet Nayak, Jennifer A Calvo, Sharon B Cantor

|Jun 25, 2020
Inhibition of the translesion synthesis polymerase REV1 exploits replication gaps as a cancer vulnerability.

Sumeet Nayak, Jennifer A Calvo, Ke Cong

|Jan 13, 2019
TPX2 joins 53BP1 to maintain DNA repair and fork stability.

Sharon Cantor

|Mar 05, 2015
Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4.

Shawna Guillemette, Ryan W Serra, Min Peng

Pageof 2

Frequent Collaborators

2 joint publications

Sumeet Nayak

1 joint publications

Jennifer A Calvo

1 joint publications

Ke Cong

1 joint publications

Nathan MacGilvary